Merck
KGaA to try again to get approval for MS pill cladribine
Send a link to a friend
[September 11, 2015] By
Ludwig Burger
FRANKFURT (Reuters) - Germany's Merck KGaA
is to seek approval from Europe's regulators for the use of its
cladribine tablet to treat multiple sclerosis, in a fresh attempt to
enter a multi-billion dollar market for a drug it had given up on four
years ago.
|
In 2011 U.S. drug regulators' concerns about whether cladribine
could cause cancer put an end to Merck's development and marketing
plans for the drug.
At the time, it was conducting Phase III trials, which the company
says have since yielded new insights.
"The decision follows the company's evaluation of new data and
additional analyses of the compound's benefit-risk profile," the
company said in a statement.
A spokeswoman declined to comment further on the findings or where
the new data came from. Fresh trials were not carried out.
But the move signals confidence that cladribine could hold its own
in an oral MS drugs market that has become increasingly crowded
since Merck pulled the plug on its project in 2011.
Biogen's Tecfidera, with $2.9 billion in sales last year, looks the
strongest contender in the class after it became the third oral MS
drug to get to market after Gilenya from Novartis, with $2.5 billion
in sales, and Sanofi's Aubagio, with 433 million euros ($489
million) in sales.
All three are taking market share from established injectable MS
drugs such as Merck KGaA's Rebif, Teva's Copaxone and Bayer's
Betaferon/Betaseron.
[to top of second column] |
Merck said it sent a letter of intent to European healthcare
regulators to meet certain requirements before it can submit the
official request for approval.
The company is also looking to seek approvals in other markets.
The additional costs of getting approval are limited because Merck
has already finished the third and last stage of testing on humans
that is required for approval, and which is by far the most
expensive phase during the development cycle.
(Editing by Greg Mahlich)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|